Title:
COMPOSITION CONTAINING ARIPIPRAZOLE AS ACTIVE INGREDIENT FOR ENHANCING ANTICANCER EFFECT OF KRAS G12C GENETIC MUTATION THERAPEUTIC AGENT
Document Type and Number:
WIPO Patent Application WO/2023/219409
Kind Code:
A1
Abstract:
The present invention relates to a composition containing aripiprazole as an active ingredient for enhancing the anti-cancer effect of a KRAS G12C genetic mutation therapeutic agent. More specifically, the present invention concerns a composition for enhancing the anticancer effect of a KRAS G12C genetic mutation therapeutic agent, which acts as an enhancer for the anti-cancer effect of the KRAS G12C genetic mutation therapeutic agent when used in combination therapy with aripiprazole, thereby enabling the treatment of cancer. When used at an effective dose in combination with a KRAS G12C genetic mutation therapeutic agent, aripiprazole according to the present invention excellently enhances the anticancer effect of the KRAS G12C genetic mutation therapeutic agent by inducing cancer cell death, etc. Thus, it can be advantageously used as an enhancer for the anti-cancer effect of the KRAS G12C genetic mutation therapeutic agent.
More Like This:
Inventors:
LIM YOUNG BIN (KR)
LEE HAE JUNE (KR)
KIM KWANG SEOK (KR)
LEE SOO HO (KR)
LEE HAE JUNE (KR)
KIM KWANG SEOK (KR)
LEE SOO HO (KR)
Application Number:
PCT/KR2023/006331
Publication Date:
November 16, 2023
Filing Date:
May 10, 2023
Export Citation:
Assignee:
KOREA INST RADIOLOGICAL & MEDICAL SCIENCES (KR)
International Classes:
A61K31/496; A23L33/10; A61K31/519; A61K45/06; A61P35/00
Foreign References:
| KR20220036878A | 2022-03-23 | |||
| KR20200111386A | 2020-09-29 | |||
| KR20170026115A | 2017-03-08 |
Other References:
KIM JI YEONG, TAE IN HWAN, LEE BYUNG-MU, KIM HYUNG SIK, YOON SUNGPIL: "Low Doses of the Anti-psychotic Drug Aripiprazole Have Strong P-gp-inhibitory Activity and Sensitize Anti-mitotic Drug-resistant Cancer Cells", ANTICANCER RESEARCH, INTERNATIONAL INSTITUTE OF ANTICANCER RESEARCH, GR, vol. 38, no. 9, 1 September 2018 (2018-09-01), GR , pages 5101 - 5108, XP093106855, ISSN: 0250-7005, DOI: 10.21873/anticanres.12830
SHUHEI SUZUKI, MASASHI OKADA, KENTA KURAMOTO, HIROYUKI TAKEDA, HIROTSUGU SAKAKI, HIKARU WATARAI, TOMOMI SANOMACHI, SHIZUKA SEINO, : "Aripiprazole, an Antipsychotic and Partial Dopamine Agonist, Inhibits Cancer Stem Cells and Reverses Chemoresistance", ANTICANCER RESEARCH, INTERNATIONAL INSTITUTE OF ANTICANCER RESEARCH, GR, vol. 36, no. 10, 12 October 2016 (2016-10-12), GR , pages 5153 - 5162, XP055405053, ISSN: 0250-7005, DOI: 10.21873/anticanres.11085
BADRAN ADNAN, TUL-WAHAB ATIA, ZAFAR HUMAIRA, MOHAMMAD NAYAB, IMAD REHAN, ASHFAQ KHAN MARIAM, BAYDOUN ELIAS, CHOUDHARY M. IQBAL: "Antipsychotics drug aripiprazole as a lead against breast cancer cell line (MCF-7) in vitro", PLOS ONE, vol. 15, no. 8, pages e0235676, XP093106858, DOI: 10.1371/journal.pone.0235676
KIM MI SEON, BYONG CHUL YOO, WOO SEOK YANG, SANG YUN HAN, DEOK JEONG, JUN MIN SONG, KYUNG HEE KIM, ADITHAN ARAVINTHAN, JI HYE KIM: "Src is the primary target of aripiprazole, an atypical antipsychotic drug, in its anti-tumor action", ONCOTARGET., vol. 9, no. 5, 1 January 2018 (2018-01-01), pages 5979 - 5992, XP093106860, DOI: 10.18632/oncotarget.23192
SHUHEI SUZUKI, MASASHI OKADA, KENTA KURAMOTO, HIROYUKI TAKEDA, HIROTSUGU SAKAKI, HIKARU WATARAI, TOMOMI SANOMACHI, SHIZUKA SEINO, : "Aripiprazole, an Antipsychotic and Partial Dopamine Agonist, Inhibits Cancer Stem Cells and Reverses Chemoresistance", ANTICANCER RESEARCH, INTERNATIONAL INSTITUTE OF ANTICANCER RESEARCH, GR, vol. 36, no. 10, 12 October 2016 (2016-10-12), GR , pages 5153 - 5162, XP055405053, ISSN: 0250-7005, DOI: 10.21873/anticanres.11085
BADRAN ADNAN, TUL-WAHAB ATIA, ZAFAR HUMAIRA, MOHAMMAD NAYAB, IMAD REHAN, ASHFAQ KHAN MARIAM, BAYDOUN ELIAS, CHOUDHARY M. IQBAL: "Antipsychotics drug aripiprazole as a lead against breast cancer cell line (MCF-7) in vitro", PLOS ONE, vol. 15, no. 8, pages e0235676, XP093106858, DOI: 10.1371/journal.pone.0235676
KIM MI SEON, BYONG CHUL YOO, WOO SEOK YANG, SANG YUN HAN, DEOK JEONG, JUN MIN SONG, KYUNG HEE KIM, ADITHAN ARAVINTHAN, JI HYE KIM: "Src is the primary target of aripiprazole, an atypical antipsychotic drug, in its anti-tumor action", ONCOTARGET., vol. 9, no. 5, 1 January 2018 (2018-01-01), pages 5979 - 5992, XP093106860, DOI: 10.18632/oncotarget.23192
Attorney, Agent or Firm:
TAEBAEK INTELLECTUAL PROPERTY LAW FIRM (KR)
Download PDF: